219 related articles for article (PubMed ID: 19748671)
1. Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190(BCR-ABL) oncoprotein and JAK2V617F mutation.
Caocci G; Atzeni S; Orrù N; Littera R; Culurgioni F; Marongiu F; La Nasa G
Leuk Res; 2010 Jan; 34(1):e27-9. PubMed ID: 19748671
[No Abstract] [Full Text] [Related]
2. Chronic myeloid leukemia with an e13a3 BCR-ABL fusion: benign course responsive to imatinib with an RT-PCR advisory.
Snyder DS; McMahon R; Cohen SR; Slovak ML
Am J Hematol; 2004 Feb; 75(2):92-5. PubMed ID: 14755375
[TBL] [Abstract][Full Text] [Related]
3. Complete response to imatinib mesylate treatment in a 12-month-old patient with chronic myeloid leukemia.
Arancibia AM; Bendit I; Epelman S
Pediatr Blood Cancer; 2008 May; 50(5):1078. PubMed ID: 18085674
[No Abstract] [Full Text] [Related]
4. E355G mutation appearing in a patient with e19a2 chronic myeloid leukaemia resistant to imatinib.
Bennour A; Beaufils N; Sennana H; Meddeb B; Saad A; Gabert J
J Clin Pathol; 2010 Aug; 63(8):737-40. PubMed ID: 20702476
[TBL] [Abstract][Full Text] [Related]
5. Molecular response to imatinib in patient with Ph negative p190 BCR-ABL transcript positive chronic myeloid leukemia with cyclic leukocytosis.
Radojkovic M; Ristic S; Pavlovic S; Colovic M
Leuk Res; 2009 Jun; 33(6):e10-2. PubMed ID: 19091403
[TBL] [Abstract][Full Text] [Related]
6. Prolonged treatment with imatinib mesylate in patients with advanced chronic myeloid leukemia causes a reduction of bcr/abl mRNA levels independent of cytogenetic response.
Cariani E; Capucci M; Micheletti M; Spalenza F; Zanella I; Albertini A; Rossi G
Ann Hematol; 2003 Jun; 82(6):333-5. PubMed ID: 12734675
[TBL] [Abstract][Full Text] [Related]
7. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
[TBL] [Abstract][Full Text] [Related]
8. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
Qin YZ; Ruan GR; Liu YR; Li JL; Fu JY; Wang H; Chang Y; Jiang B; Jiang Q; Jiang H; Qiu JY; Chen SS; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498
[TBL] [Abstract][Full Text] [Related]
9. JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia.
Campiotti L; Appio L; Solbiati F; Ageno W; Venco A
Leuk Res; 2009 Nov; 33(11):e212-3. PubMed ID: 19589593
[No Abstract] [Full Text] [Related]
10. [Detection and quantification of BCR-ABL transcripts in patients with chronic myeloid leukemia by real-time quantitative reverse transcriptase polymerase chain reaction].
Xing W; Gu BW; Zhu YM; Jiang CL; Zhao RH; Wang AH; Sun HP; Li JM; Shen ZX; Chen Z; Chen SJ
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):453-7. PubMed ID: 15854550
[TBL] [Abstract][Full Text] [Related]
11. Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients.
Bianchini M; De Brasi C; Gargallo P; Gonzalez M; Bengió R; Larripa I
Eur J Haematol; 2009 Apr; 82(4):292-300. PubMed ID: 19191867
[TBL] [Abstract][Full Text] [Related]
12. Differential molecular response of the transcripts B2A2 and B3A2 to imatinib mesylate in chronic myeloid leukemia.
de Lemos JA; de Oliveira CM; Scerni AC; Bentes AQ; Beltrão AC; Bentes IR; Azevedo TC; Maradei-Pereira LM
Genet Mol Res; 2005 Dec; 4(4):803-11. PubMed ID: 16475128
[TBL] [Abstract][Full Text] [Related]
13. [Analysis of ABL tyrosine kinase point mutations in imatinib treated chronic myelogenous leukemia patients].
Qin YZ; Liu YR; Li JL; Ruan GR; Zhu HH; Jiang Q; Fu JY; Lu Y; Chang Y; Li LD; Huang XJ; Chen SS; Qiu JY
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(45):3186-9. PubMed ID: 16405837
[TBL] [Abstract][Full Text] [Related]
14. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.
Frater JL; Tallman MS; Variakojis D; Druker BJ; Resta D; Riley MB; Hrisinko MA; Peterson LC
Am J Clin Pathol; 2003 Jun; 119(6):833-41. PubMed ID: 12817431
[TBL] [Abstract][Full Text] [Related]
15. CML patient with rare b 2 a 3 (e 13 a 3) variant of BCR-ABL transcript: complete molecular response to imatinib.
Moravcová J; Rulcová J; Polák J; Zemanová Z; Klamová H; Haskovec C
Leuk Res; 2005 Nov; 29(11):1365-6. PubMed ID: 15876454
[No Abstract] [Full Text] [Related]
16. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria.
Branford S; Seymour JF; Grigg A; Arthur C; Rudzki Z; Lynch K; Hughes T
Clin Cancer Res; 2007 Dec; 13(23):7080-5. PubMed ID: 18056186
[TBL] [Abstract][Full Text] [Related]
17. Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase.
Moravcová J; Zmeková V; Klamová H; Voglová J; Faber E; Michalová K; Rabasová J; Jarosová M
Leuk Res; 2004 Apr; 28(4):415-9. PubMed ID: 15109543
[TBL] [Abstract][Full Text] [Related]
18. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
19. JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders.
Cambier N; Renneville A; Cazaentre T; Soenen V; Cossement C; Giraudier S; Grardel N; Laï JL; Rose C; Preudhomme C
Leukemia; 2008 Jul; 22(7):1454-5. PubMed ID: 18288134
[No Abstract] [Full Text] [Related]
20. Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript.
Pienkowska-Grela B; Woroniecka R; Solarska I; Kos K; Pastwińska A; Konopka L; Majewski M
Cancer Genet Cytogenet; 2007 Apr; 174(2):111-5. PubMed ID: 17452251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
